Mark C. McKenna
CIK 1749623 · Chairman, President and CEO · last filed 2026-09-03
Mark C. McKenna is a Chairman, President and CEO who has filed 30 SEC Form 4 insider transactions across 7 companies since 2019. The most recent filing, for APGE, was dated Sep 3, 2026. Across all open-market trades the lifetime net is −$14.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $243.7K across reported positions. 7 SEC filings were submitted jointly with Bausch Health Companies Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$243.7K
7
30
-$14.23M
Filer Profile
BRIDGEWATER, NJ 08807
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| APGE | Director | 0 | $135.07 | $0 | $990.8K | 6 | 2026-09-03 |
| FRNM | 30,000 | — | — | $0 | 1 | 2026-07-22 | |
| SYRE | Director | — | $90.60 | — | $0 | 3 | 2026-05-29 |
| NAMSW | Director | 10,360 | $11.78 | $122.0K | $0 | 3 | 2026-01-09 |
| BridgeBio Oncology Therapeutics, Inc. (HLXB) Delisted | 30,000 | $9.90 | $297.0K | $0 | 1 | 2025-08-11 | |
| Prometheus Biosciences, Inc. (RXDX) Delisted | Chairman, President and CEO | 0 | $199.92 | $0 | -$14.99M | 10 | 2023-06-16 |
| BHC | President, Salix | 20,756 | $5.86 | $121.6K | -$235.2K | 6 | 2019-08-21 |
Recent Filings
30 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-03 | APGE | Disp (D) | −20,000 | $0 | EDGAR |
| 2026-07-22 | FRNM | Conv (C) | +30,000 | $0 | EDGAR |
| 2026-06-11 | APGE | Grant (A) | — | $0 | EDGAR |
| 2026-05-29 | SYRE | Grant (A) | — | $0 | EDGAR |
| 2026-01-09 | NAMSW | Grant (A) | +3,400 | $0 | EDGAR |
| 2025-08-11 | BridgeBio Oncology Therapeutics, Inc. (HLXB) Delisted | Exer (M) | +30,000 | $0 | EDGAR |
| 2025-06-20 | APGE | Grant (A) | — | $0 | EDGAR |
| 2025-06-02 | SYRE | Grant (A) | — | $0 | EDGAR |
| 2025-01-08 | NAMSW | Grant (A) | +6,960 | $0 | EDGAR |
| 2024-12-16 | APGE | Buy (P) | +20,000 | $990.8K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.